



**RIGHT FUND**

**2018/19**



## A Small First Step to Make a Big Impact

The RIGHT Fund is approaching its one-year anniversary, and we are proud to share our accomplishments with our existing and potential partners.

The RIGHT (Research Investment for Global Health Technology) Fund is the first public private partnership built between three different funding sectors—the Korean government, Korean industries, and international funders—with the mission of enhancing public health in developing countries.

The RIGHT Fund has been established and will serve as the platform for the Korean government to contribute to developing countries, and for Korean industries to introduce direct and innovative solutions for public health leveraging their own R&D strengths. The technological advancements that will be financed and generated through the RIGHT Fund will not only benefit the target countries, but will also bring about innovations to improve global health.

Since the legal registration of the RIGHT Fund in July 2018, we together with our officers and team members have established our governance & management, business model, and investment priorities & process. In October 2018, we issued our first call for proposals and we are about to announce our first awardees.

This is only the first step. We see that there are many more investment opportunities where the RIGHT Fund can make a large impact, and good partnerships are critical for achieving these goals.

We appreciate all of the support from our existing partners, and we continue to seek new partnerships to help us make progress toward our mission.

CHAIRMAN OF THE BOARD  
CHANGJIN MOON

문창진

CEO & EXECUTIVE DIRECTOR  
YOUNBEEN KIM

Younbeen Kim

## Who we are

Established in 2018 and based in Seoul, the RIGHT Fund is the first public private partnership between the Korean Government, Korean pharma companies, and the Bill and Melinda Gates Foundation.

Seeking practical investments on projects to deliver tangible global health solutions, we invest in original and innovative concepts for vaccines, therapeutics, and diagnostics to alleviate the acquisition, progression, or transmission of infectious diseases emerging and endemic in developing countries through our annual call for proposals.

## Vision

*To alleviate the burden of infectious diseases that disproportionately affect the people in low-resource countries*



## Mission


*To mobilize Korea's innovation and leadership to advance global health equity by promoting the discovery and development of new technologies that will meet the public health needs of developing countries*





# Funding Partners

2018-2022 Total Funding



# Investment Priorities 2018-2022

The RIGHT Fund seeks to improve global health through innovative health intervention technologies relating to diagnostics, vaccines, and drugs




- 01** FOCUS ON UNMET MEDICAL NEEDS

  - Projects addressing specific unmet needs (e.g. lack of treatment options, patient access, and usage, high cost, etc.)
  - Projects that maximize impact on public health (lives saved and DALYS)
- 02** LEVERAGE KOREAN INDUSTRIAL STRENGTHS


  - Identify projects that best utilize emerging or specific technologies based on the strengths of Korean industry
  - Foster collaboration among local and international organizations
- 03** BUILD CAPACITY FOR KOREAN RESEARCH AND DEVELOPMENT

  - Projects that can enrich the local pipeline for public health indications
  - Support the localization of product development and manufacturing
- 04** EXTEND THE ENGAGEMENT OF KOREAN INDUSTRY, R&D ORGANIZATIONS, AND INSTITUTIONS WITH GLOBAL HEALTH INITIATIVES

# Focused Investment Area

			
	VACCINES	THERAPEUTICS	DIAGNOSTICS
NEW APPROACHES & CONSTRUCTS	<ul style="list-style-type: none"><li>• New vaccines for target diseases</li><li>• New pediatric combination vaccines</li></ul>	<ul style="list-style-type: none"><li>• New chemical or biological approaches for currently unmet needs</li></ul>	<ul style="list-style-type: none"><li>• New diagnostics and those that can improve efficiency of treatments</li><li>• Point-of-Care diagnostics</li><li>• Proof of concept for ICT combined diagnostics</li></ul>
PRODUCT IMPROVEMENTS	<ul style="list-style-type: none"><li>• Improvements in immunization schedule, production method, thermostability, administration routes</li></ul>	<ul style="list-style-type: none"><li>• Incrementally modified drugs</li><li>• New treatment regimens and modifications that improve drug uptake and outcomes</li></ul>	<ul style="list-style-type: none"><li>• Improvements in existing diagnostics for use in low-resource countries</li></ul>
PATIENT ACCESS	<ul style="list-style-type: none"><li>• Interventions seeking or nearing WHO PQ</li><li>• Lower-cost manufacturing platforms</li></ul>	<ul style="list-style-type: none"><li>• Interventions seeking or nearing WHO PQ</li><li>• Lower-cost manufacturing platforms</li></ul>	<ul style="list-style-type: none"><li>• Proof of concept for ICT applied patient access tools or surveillance</li></ul>

## Eligible Development Stages





# Leadership




To mitigate any conflicts of interests, the RIGHT Fund has adopted a governance structure that ensures a transparent and equitable framework for the selection and advancement of new healthcare innovations, and access to them.

A well-planned and interlocking set of leadership bodies and functions has been designed to achieve this goal. The RIGHT Fund leadership team is organized into four separate but related bodies—the Board of Directors, Council, Selection Committee, and Management Team—that perform independent roles and collectively contribute to achieve the goals of the organization.

## Board of Directors

The highest decision-making body of the RIGHT Fund, comprising global health experts and management professionals. As an important complement to this role, the Board applies self-governance to ensure that it is functioning in a manner that enables responsible and unbiased resolutions for the benefit of the RIGHT Fund.

CHAIRMAN






CHANGJIN MOON

YOUNBEEN KIM

IN-TAEK LIM

YOUNGMEE JEE



GLENN ROCKMAN

KIM C. BUSH

PETER HOTEZ

ANDRIN OSWALD





## Council

Comprises representatives from founding and funding organizations that have agreed to the purpose of the RIGHT Fund. The Council is the highest advisory body of the RIGHT Fund and may provide professional recommendations for the consideration of the Board of Directors.



## Selection Committee

CHAIRMAN







PAUL L. HERRLING, PH.D.  
Former head of Corporate Research at Novartis and the Chairman of the Board of the Novartis Institute for Tropical Diseases

ANN MILLS-DUGGAN, PH.D.  
Partner, Innovations Wellcome Trust

MELISSA A. MALHAME, MBA  
Principal, MM Global Health Consulting LLC

INSOO KIM, PH.D.  
CEO&Founder of Eupidia Co.,Ltd and Adjunct Professor of Sogang University



CHRISTIAN LIENHARDT, MD, DTM, MSc, PH.D.  
Research Director, French National Research Institute for Development

GERALD VOSS, PH.D.  
Executive Director, SciPeo Sprl, Science and People

JOON HAENG RHEE, MD, PH.D.  
Professor of Microbiology, Chonnam National University Medical School

DAN WATTENDORF, MD  
Director of Innovative Technology Solutions, Bill and Melinda Gates Foundation

Comprises domestic and international experts with extensive knowledge and experience in research and development of drugs, vaccines, and diagnostics. The Selection Committee is the key decision-making body in reviewing applications and awarding investments in this area. This committee evaluates investment proposals and reports from development partners, and recommends investments to the Board of Directors.








## External Reviewers

These experts provide vital support that is critical to the work of the RIGHT Fund.

AJOY CHAKRABARTI	ANN GINSBERG	CARL KIRKWOOD	YEONG MIN PARK	GAUTAM SANYAL	JELLE THOLE
GERARD CUNNINGHAM	TAI HWAN HA	DAVE LAFFAN	TREVOR PERRIOR	WOO KYEONG SEONG	KAMALA THRIEMER
ANDREAS DIACON	PHILIP HILL	JOEL LEONG	RENAUD PIARROUX	AJIT PAL SINGH	NADIA G. TORNIEPORTH
LAURA DIGILIO	JINHO HYUN	YVONNE A. MALDONADO	MICHAEL POLLASTRI	BOB SNOW	NICHOLAS WHITE
JOHN DONNELLY	ANNE KASMAR	YUKARI MANABE	DOMINICK PUCCI	DAESUB SONG	
MALCOLM DUTHIE	MARCEL VAN KASTEEL	ANNA MANDALAKAS	GEORGE ROBERTSON	ANITA SURESH	
ABDELATIF ELOUAHABI	YEUCHUN KIM	FLOR MUNOZ	DAVID ROBINSON	MARCEL TANNER	

## Management Team

Responsible for the design and development of business and investment strategies for the RIGHT Fund. Upon approval from the Board of Directors, the Management Team is responsible for the execution of strategies, administrative operation, and organizational growth of the Fund.



YOUNBEEN KIM  
CEO & EXECUTIVE DIRECTOR

BRYAN K.S. YEUNG  
SENIOR DIRECTOR OF STRATEGY

JUNGJAE SHIM  
DIRECTOR OF GOV'T AFFAIRS AND OPERATIONS

YOONYOUNG DO  
FINANCE AND OPERATIONS OFFICER

KYUNG HWA SONG  
SECRETARY / ADMINISTRATIVE OFFICER

SABINNE KIM  
DIRECTOR OF INVESTMENT PLANNING AND MANGEMENT

BORA VIOLE KIM  
PROGRAM ASSOCIATE



# RIGHT FUND

Research Investment for Global Health Technology Fund

<b>Location</b>	International Vaccine Institute 2nd Floor, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, South Korea #08826
<b>Phone</b>	+82-2-6337-9400
<b>E-mail</b>	<a href="mailto:rightinfo@rightfund.org">rightinfo@rightfund.org</a>
<b>Linkedin</b>	<a href="http://www.linkedin.com/company/rightfund">www.linkedin.com/company/rightfund</a>
<b>Website</b>	<a href="http://www.rightfund.org">www.rightfund.org</a>